Sentence examples for validation of biomarker from inspiring English sources

Understanding the impact of these variables is critical for accurate quantification and validation of biomarker measurements.

Systematic evaluation and implementation of these design strategies in the phase II setting are essential for accelerating the clinical validation of biomarker guided-therapy.

The last section describes the bridging of biomarkers from preclinical laboratory studies into the clinical realm, and the necessary considerations in terms of technical validation of biomarker endpoints, the role of biomarkers as surrogate endpoints and in pharmacokinetic/pharmacodynamic modeling, and how biomarkers may be viewed in a regulatory context.

Additionally, the ELISA assay enables detection of a single antigen, a drawback for the validation of biomarker panels.

This includes untargeted platforms for biomarker identification (gel-based and gel-free) [70, 71, 178 182] and targeted platforms for further verification and validation of biomarker candidates (MRM, multi-analyte assays) [106, 108, 115, 183, 184].

Variations in functional conservations and regulatory circuits necessitates a profound validation of biomarker quality, and our study provides a quantitative approach to systematically search for these biomarkers and to evaluate their predictive potential.

We analyzed data drawn from a multi-ICU, prospective cohort study, entitled the Validation of biomarkers in Acute Lung Injury Diagnosis (VALID) study, the primary purpose of which is to identify biomarkers of diagnosis and prognosis in ARDS.

In spite of the large literature on developing predictive biomarkers, there is considerable confusion about the development and validation of biomarker-based diagnostic classifiers for treatment selection.

Identification and validation of biomarkers is increasingly important for the integration of novel targeted agents in the treatment of cancer.

We show that innate immune and cytokine responses following infection with HBV mimic those observed in HBV-infected patients, thus allowing the dissection of pathways important for immune evasion and validation of biomarkers.

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of clinical features, but current knowledge gaps, including validation of biomarkers and treatment algorithms, limit practical implementation.